ZGNX
Price:
$26.68
Market Cap:
$0
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a ...[Read more]
Industry
Biotechnology
IPO Date
2010-11-23
Stock Exchange
NASDAQ
Ticker
ZGNX
According to Zogenix, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.56. This represents a change of 56.16% compared to the average of -4.20 of the last 4 quarters.
The mean historical PE Ratio of Zogenix, Inc. over the last ten years is -1.04. The current -6.56 PE Ratio has changed 62.68% with respect to the historical average. Over the past ten years (40 quarters), ZGNX's PE Ratio was at its highest in in the June 2014 quarter at 1.12. The PE Ratio was at its lowest in in the December 2012 quarter at -52.08.
Average
-1.04
Median
-4.47
Minimum
-11.15
Maximum
22.75
Discovering the peaks and valleys of Zogenix, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 104.29%
Maximum Annual PE Ratio = 22.75
Minimum Annual Increase = -592.57%
Minimum Annual PE Ratio = -11.15
Year | PE Ratio | Change |
---|---|---|
2021 | -3.84 | -25.15% |
2020 | -5.13 | -4.23% |
2019 | -5.35 | -52.00% |
2018 | -11.15 | 29.32% |
2017 | -8.62 | 99.58% |
2016 | -4.32 | -135.72% |
2015 | 12.09 | -46.85% |
2014 | 22.75 | -592.57% |
2013 | -4.62 | 104.29% |
2012 | -2.26 | 100.07% |
The current PE Ratio of Zogenix, Inc. (ZGNX) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.77
5-year avg
-6.82
10-year avg
-1.04
Zogenix, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zogenix, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Zogenix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Zogenix, Inc.'s PE Ratio?
How is the PE Ratio calculated for Zogenix, Inc. (ZGNX)?
What is the highest PE Ratio for Zogenix, Inc. (ZGNX)?
What is the 3-year average PE Ratio for Zogenix, Inc. (ZGNX)?
What is the 5-year average PE Ratio for Zogenix, Inc. (ZGNX)?
How does the current PE Ratio for Zogenix, Inc. (ZGNX) compare to its historical average?